Last reviewed · How we verify
HSK21542 tablet
HSK21542 is a small-molecule inhibitor that targets specific kinases involved in cellular signaling pathways.
HSK21542 is an investigational drug developed by Xizang Haisco Pharmaceutical Co., Ltd. It is currently in Phase 2 trials for chemotherapy-induced nausea and vomiting, peritoneal dialysis pruritus, and sleep quality in hemodialysis patients with CKD-aP. The drug has not yet received FDA approval.
At a glance
| Generic name | HSK21542 tablet |
|---|---|
| Also known as | HSK21542, HSK21542 0.2 μg/kg, HSK21542 0.5 μg/kg, HSK21542 1 μg/kg, HSK21542 0.75 μg/kg |
| Sponsor | Xizang Haisco Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
While detailed mechanistic information is limited in public sources, HSK21542 appears to function as a kinase inhibitor developed for oncological applications. The drug is marketed in China by Xizang Haisco Pharmaceutical, suggesting it has completed clinical development and regulatory approval in that region.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK21542 tablet CI brief — competitive landscape report
- HSK21542 tablet updates RSS · CI watch RSS
- Xizang Haisco Pharmaceutical Co., Ltd portfolio CI